

Linearity LQ Protein



Aalto Scientific Ltd
230 Technology Pkwy
Eatonton, GA 31024
USA



REF K702M-5

5 x 2 mL

LOT 07180A, 07180B, 07180C,
07180D, 07180E



2027-12-19

INTENDED USE

The Linearity LQ Protein is assayed quality control material consisting of five levels of human based serum. Each level contains the following analytes: AAT, B2M, C3, C4, IgA, IgG, IgM, PALB, TRF, and TP. These five levels demonstrate a linear relationship to each other for their respective analytes¹. It is intended to simulate human patient serum samples for purpose of determining linearity, calibration verification and verification of reportable range for AAT, B2M, C3, C4, IgA, IgG, IgM, PALB, TRF, and TP.

This product is intended for use with quantitative assays on the indicated analyzer provided in the labeling. The Linearity LQ Protein should not be used for calibration or standardization of the AAT, B2M, C3, C4, IgA, IgG, IgM, PALB, TRF, and TP assays. The Linearity LQ Protein is for "In Vitro Diagnostic use only."

SUMMARY AND PRINCIPLE

As defined in the Clinical Laboratory Improvement Amendments of 1988 (CLIA) by the Centers for Medicare and Medicaid Services (CMS) and the Centers for Disease Control (CDC), each laboratory must revalidate each test method's AMR at least every six months as well as following changes in lots of analytically critical reagents or major system components². Good laboratory practices require that stable reference materials be used to verify the accuracy and precision of testing methods and techniques. Linearity LQ Protein may be used as one would use human serum to verify and validate the AMR.

WARNINGS AND PRECAUTIONS

Because this product is of human origin, it should be handled as though capable of transmitting infectious diseases. Each serum, plasma or whole blood donor unit used in the preparation of this material was tested by United States Food and Drug Administration (FDA) approved methods and found to be negative for antibodies to HIV and HCV and nonreactive for HBsAg. Because no test method can offer complete assurance that HIV, hepatitis B virus, and hepatitis C virus or other infectious agents are absent, this material should be handled as though capable of transmitting infectious diseases. This product may also contain other human source material for which there is no approved test. The FDA recommends such samples be handled at the Centers for Disease Control's Biosafety Level 2.

This product contains less than 0.1% sodium azide that may react with lead and copper plumbing to form potentially explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up.

Linearity LQ Protein is intended solely for the purpose of in vitro diagnostic use as described on the label. Audit® MicroControls™, Inc. will not be liable for any unclaimed damages arising from any other usage.

MATERIALS PROVIDED

Linearity LQ Protein, 5 x 2 mL

STORAGE AND STABILITY

Linearity LQ Protein is stored at 2-8°C and will remain stable in the unopened vial until the expiration date. After opening, the contents should be used according to the instrument manufacturer's instructions and immediately returned to 2-8°C.

When used to monitor the precision of laboratory testing procedures for its assays, Linearity LQ Protein has an open vial stability of up to 5 days under the proper storage conditions. Leaving the vial uncapped, or prolonging its time at room temperature, will void this open vial stability claim. Make sure the contents of the vial are well mixed before use.

PROCEDURE

Follow the manufacturer's instructions provided for quality control and for verifying and validating the AMR. Verify that the lot number on each vial matches the package insert. To avoid evaporation, do not leave the vial uncapped. Q.C. requirements should be performed in conformance with local, state and/or federal regulations or accreditation requirements. Calibration verification linearity material should be run³:

- every six (6) months.
- when a complete change of reagents for a procedure is introduced.
- when there is major preventive maintenance or replacement of critical parts that may influence test performance.
- when control materials reflect an unusual trend or shift, or are outside of the laboratory's acceptable limits.
- when the laboratory's established schedule for verifying the reportable range for patient test results requires more frequent calibration verification.

INSTRUCTIONS FOR USE

- Remove a vial from the package and mix by gentle inversion. Do not shake. Do not mix mechanically.
- Use immediately or return to 2-8°C.
- The vial should remain stored at 2-8°C at all times. If additional sampling is necessary, the time outside of 2-8°C storage should be minimized.

CALCULATIONS OF RESULTS

Each set of Linearity LQ Protein is prepared in a manner such that an equal distance exists

between each consecutive level. This dilution scheme is consistent with the CLSI recommendation¹ for preparing linearity sets.

U.S. customers only - Once each vial of the total set is tested, raw data may be entered via the AUDITOR™ QC Program at www.auditmicro.com. An on-line graph showing actual values versus predicted values for each analyte is then available to print, along with slope and intercept data. Call (866) 25-AUDIT for more information.

LIMITATIONS OF THE PROCEDURE

If the contents of any of the vials become frozen, discard all vials and request a replacement set, as the results will not be valid.

Dispose of any discarded materials in accordance with the requirements of your local waste management authorities.

EXPECTED VALUES

Each lot of product is manufactured such that a linear relationship exists among levels. The analyte concentrations in this insert were derived from multiple replicate analyses. Actual results obtained may vary depending on instrumentation, methodology and assay temperature. Results may also be dependent on the accuracy of the instrument/reagent system calibration. The degree of acceptable non-linearity is an individual judgment based on methodology, clinical significance and medical decision levels of the test analyte. The material and information presented here in no manner constitutes an overruling of any federal, state or other regulatory body's regulations and/or guidelines.

ORDERING INFORMATION

PRODUCT NUMBER	PRODUCT DESCRIPTION	PRODUCT PACKAGING
K702M-5	Linearity LQ Protein	5 x 2 mL

Distributed by Audit® MicroControls™, Inc. - U.S. customers only please call (866) 252-8348 or www.auditmicro.com

¹ Dilution schemes are based on guidelines provided by The Clinical and Laboratory Standard Institute (CLSI) in approved guideline EP6-A, "Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline", April 2003.

² Federal Register 42 CFR Part 493, Department of Health and Human Services, January 24, 2003; p.3690.

³ Federal Register 42 CFR Part 493, Department of Health and Human Services, January 24, 2003; §493.1255, (b) (1) (ii).

	Units	Instrument, Reagent	A	B	C	D	E
AAT	mg/dL	Cobas c501, Roche	29	150	277	401	519
B2M	mg/L	Cobas c501, Roche	0.28	2.08	3.76	5.24	7.12
C3	mg/dL	Cobas c501, Roche	18	108	208	316	413
C4	mg/dL	Cobas c501, Roche	4	25	48	72	94
IgA	mg/dL	Cobas c501, Roche	58	204	364	523	670
IgG	mg/dL	Cobas c501, Roche	328	1191	2164	3332	4281
IgM	mg/dL	Cobas c501, Roche	30	147	271	358	527
PALB	mg/dL	Cobas c501, Roche	4	25	46	64	>80
TRF	mg/dL	Cobas c501, Roche	27	190	356	486	>520
TP	g/dL	Cobas c501, Roche	1.0	5.7	10.2	>12	>12